Cargando…

T216. VARIATION IN SIDE EFFECTS TO ANTIPSYCHOTIC TREATMENT ACROSS SCHIZOPHRENIA SPECTRUM DISORDERS

BACKGROUND: Adverse effects of antipsychotic drugs play a key role in non-compliance and discontinuation of treatment in Schizophrenia Spectrum Disorders (SSD). Precision medicine aims to minimize such adverse effects by selecting the right treatment for the right patients. To determine the need for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Susanne Neumeier, Maria, Winkelbeiner, Stephanie, Kane, John, Seifritz, Erich, Huhn, Maximilian, Leucht, Stefan, Homan, Philipp
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Session III
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234661/ http://dx.doi.org/10.1093/schbul/sbaa029.776

Ejemplares similares

T169. SEMANTIC PROCESSING IN RELATION TO ANATOMICAL INTEGRITY OF THE VENTRAL LANGUAGE STREAM IN SCHIZOPHRENIA SPECTRUM DISORDERS
por: Surbeck, Werner, et al.
Publicado: (2020)

T200. METABOLIC SIDE EFFECTS OF ANTIPSYCHOTIC DRUGS – PROTOCOL OF A SYSTEMATIC REVIEW AND NETWORK- METAANALYSIS
por: Schneider-Thoma, Johannes, et al.
Publicado: (2020)

S43. ASSESSING THE VARIABILITY OF RESPONSE TO NON-INVASIVE BRAIN STIMULATION IN PSYCHOSIS
por: Winkelbeiner, Stephanie, et al.
Publicado: (2020)

T79. BALANCING EFFECTS WITH SIDE-EFFECTS: EXAMINING COMPARATIVE METABOLIC CONSEQUENCES OF 18 ANTIPSYCHOTICS IN TREATMENT OF SCHIZOPHRENIA USING NETWORK META-ANALYSIS
por: Pillinger, Toby, et al.
Publicado: (2020)

T8. ANTIPSYCHOTIC TREATMENT AND EYE MOVEMENT ABNORMALITIES IN SCHIZOPHRENIA
por: Takahashi, Junichi, et al.
Publicado: (2020)

T45. THE EFFICACY AND HETEROGENEITY OF ANTIPSYCHOTIC RESPONSE IN SCHIZOPHRENIA: A META-ANALYSIS
por: McCutcheon, Rob, et al.
Publicado: (2020)

T220. IMPACT OF SECOND-GENERATION ANTIPSYCHOTIC SIDE EFFECTS ON FUNCTIONING FROM A SCHIZOPHRENIA PATIENT PERSPECTIVE: GLOBAL PATIENT CENTERED SURVEY INCLUDING PATIENTS FROM ITALY
por: Weiss, Catherine, et al.
Publicado: (2020)

T231. QUALITY OF LIFE IN ANTIPSYCHOTIC-NAïVE YOUTH: EXPLORING THE INTERPLAY WITH METABOLIC SIDE-EFFECTS
por: Chintoh, Araba, et al.
Publicado: (2020)

T167. QUALITATIVE DIFFERENCES IN LONG ACTING INJECTABLE ANTIPSYCHOTIC MEDICATIONS AMONG SCHIZOPHRENIA PATIENTS
por: Karakasi, Valeria, et al.
Publicado: (2020)

T211. COMPARISON OF REHOSPITALIZATION RATE IN INDIVIDUALS WITH SCHIZOPHRENIA CHANGED FROM PALIPERIDONE PALMITATE TO ORAL ANTIPSYCHOTICS
por: Ju Lee, Bong, et al.
Publicado: (2020)

T42. HIGH ADHERENCE TO CURRENT ANTIPSYCHOTIC AND ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL TO EVALUATE THE TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT
por: Abbs, Brandon, et al.
Publicado: (2020)

T28. BENEFITS AND HARMS OF ANTIPSYCHOTICS IN THE TREATMENT OF CHILDREN AND ADOLESCENTS WITH SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Hagi, Katsuhiko, et al.
Publicado: (2020)

T47. GUANFACINE AUGMENTATION OF ATTENTIONAL FUNCTIONING IN THE SCHIZOPHRENIA SPECTRUM
Publicado: (2020)

T23. ANTIPSYCHOTIC EXPOSURE AND STRIATAL FUNCTIONAL CONNECTIVITY IN PSYCHOSIS RELAPSE: A HYPOTHESIS GENERATING STUDY
por: Rubio, Jose, et al.
Publicado: (2020)

T174. ANTIPSYCHOTICS AND THE MICROBIOME
por: Chen, Anderson, et al.
Publicado: (2020)

T228. SOCIAL REWARD REACTIVITY AND SENSITIVITY IN SCHIZOPHRENIA SPECTRUM CONDITIONS
por: Aldridge-Waddon, Luke, et al.
Publicado: (2020)

T16. SCHIZOPHRENIA SPECTRUM DISORDER: DEPRESSION TRAJECTORIES AND IMMUNE MARKERS
por: Hoprekstad, Gunnhild, et al.
Publicado: (2020)

T246. RISK FACTORS FOR PSYCHOTIC RELAPSE IN CHRONIC SCHIZOPHRENIA AFTER DOSE-REDUCTION OR DISCONTINUATION OF ANTIPSYCHOTICS: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Bogers, Jan, et al.
Publicado: (2020)

T214. ANTIPSYCHOTIC TREATMENT PATTERNS AND EFFECTS DURING THE EARLY YEARS AMONG 316 NEWLY DIAGNOSED PATIENTS WITH SCHIZOPHRENIA FROM THE OPUS TRIAL
por: Albert, Nikolai, et al.
Publicado: (2020)

T62. A COMPUTATIONAL ANALYSIS OF MOTIVATIONAL DEFICITS IN SCHIZOPHRENIA SPECTRUM DISORDERS
por: Waltz, James, et al.
Publicado: (2020)

T73. COGNITIVE CLUSTERING IN SCHIZOPHRENIA SPECTRUM DISORDER AND THE ASSOCIATION WITH BRAIN VOLUME
por: Oomen, Priscilla, et al.
Publicado: (2020)

T213. TREND OF LONG-ACTING INJECTABLE ANTIPSYCHOTICS USE IN ASIA: FINDINGS FROM REAP ANTIPSYCHOTIC STUDIES
por: Lin, Shih-Ku, et al.
Publicado: (2020)

T196. THERAPEUTIC MANAGEMENT IN MULTIPLE SCLEROSIS AND SCHIZOPHRENIA SPECTRUM DISORDERS DUAL DIAGNOSIS
por: Vasiliu, Octavian
Publicado: (2020)

T106. CHILDHOOD TRAUMA IS ASSOCIATED WITH THEORY OF MIND IMPAIRMENT IN SCHIZOPHRENIA-SPECTRUM PSYCHOSIS
por: Chatziioannidis, Stylianos, et al.
Publicado: (2020)

T41. SAFETY PROFILE OF ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL FOR THE POTENTIAL TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT
por: Bugarski-Kirola, Dragana, et al.
Publicado: (2020)

T206. ANTIPSYCHOTIC EFFECTIVENESS FOCUSING ON INSIGHT
por: Stabell, Lena, et al.
Publicado: (2020)

T136. NEURAL CORRELATES OF ALTERED COGNITIVE FLEXIBILITY AND STABILITY FOR MOTOR CONTROL IN SCHIZOPHRENIA – JUST TWO SIDES OF THE SAME COIN?
por: Lencer, Rebekka, et al.
Publicado: (2020)

T194. SUBJECTIVE ANOMALIES OF IMAGINATION AGGREGATE IN SCHIZOPHRENIA-SPECTRUM DISORDERS AND ARE ASSOCIATED WITH DISORDERS OF BASIC SELF
por: Rosén Rasmussen, Andreas, et al.
Publicado: (2020)

Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland
por: Reymann, Stephan, et al.
Publicado: (2022)

T202. THE EFFECT OF ANTIPSYCHOTIC DRUGS ON MEMBRANE FUSION: AN IN VITRO STUDY
por: Adrien, Vladimir, et al.
Publicado: (2020)

T199. 7% WEIGHT CHANGE ASSOCIATED WITH ANTIPSYCHOTICS: A META-ANALYSIS
por: Crins, Joost, et al.
Publicado: (2020)

T205. LUMATEPERONE IN THE TREATMENT OF SCHIZOPHRENIA: EVALUATION OF EXTRAPYRAMIDAL AND MOTOR SYMPTOMS IN 4 LATE-PHASE CLINICAL TRIALS
por: Durgam, Suresh, et al.
Publicado: (2020)

T221. CAUSAL RELATIONSHIPS BETWEEN EMPATHY, MOTIVATION AND FUNCTIONAL OUTCOMES IN EARLY SCHIZOPHRENIA IDENTIFIED WITH CAUSAL DISCOVERY MODELING
por: Miley, Kathleen, et al.
Publicado: (2020)

Should ‘typical’, first-generation antipsychotics no longer be generally used in the treatment of schizophrenia?
por: Leucht, Stefan, et al.
Publicado: (2021)

T224. TESTING THE EFFECTIVENESS OF A BRIEF, PEER SUPPORT INTERVENTION TO FACILITATE TRANSITION FROM PSYCHIATRIC HOSPITALIZATION FOR A SCHIZOPHRENIA SPECTRUM POPULATION
por: Kidd, Sean, et al.
Publicado: (2020)

T60. GENETIC INFLUENCES ON MEMORY FUNCTIONS AND RELATED BRAIN STRUCTURES AND ASSOCIATIONS WITH SCHIZOPHRENIA SPECTRUM DISORDERS: A NATION-WIDE TWIN STUDY
por: Lemvigh, Cecilie, et al.
Publicado: (2020)

T215. THE ANTIPSYCHOTIC ACTION OF HALOPERIDOL IN PSYCHOTIC-LIKE RATS REQUIRES PRESYNAPTIC VESICULAR ACCUMULATION
por: Müller, Christian, et al.
Publicado: (2020)

T86. RELEVANCE OF CANNABIS USE AS A PREDICTOR OF CLINICAL OUTCOME IN FIRST-EPISODE SCHIZOPHRENIA SPECTRUM DISORDER PATIENTS OVER 24 MONTHS OF TREATMENT
por: Scheffler, Frederika, et al.
Publicado: (2020)

T186. IMPACT OF A STRUCTURED VALIDATED FAMILY PSYCHOEDUCATIONAL PROGRAM (PROFAMILLE) ON MENTAL HEALTH CARE OF PEOPLE WITH SCHIZOPHRENIA SPECTRUM DISORDERS: PRELIMINARY RESULTS
por: Bralet, Marie-Cécile, et al.
Publicado: (2020)

Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial
por: Huhn, Maximilian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_asikh3e0ouv9lhappuqbj9qc6b